Research Analysts’ Weekly Ratings Changes for HCA Healthcare (HCA)

Several brokerages have updated their recommendations and price targets on shares of HCA Healthcare (NYSE: HCA) in the last few weeks:

• 2/6/2026 – HCA Healthcare had its price target raised by analysts at Argus from $530.00 to $560.00. They now have a “buy” rating on the stock.
• 2/2/2026 – HCA Healthcare was given a new $540.00 price target on by analysts at Mizuho.
• 1/30/2026 – HCA Healthcare had its price target raised by analysts at Wells Fargo & Company from $452.00 to $481.00. They now have an “equal weight” rating on the stock.
• 1/28/2026 – HCA Healthcare had its “buy” rating reaffirmed by analysts at TD Cowen.
• 1/28/2026 – HCA Healthcare was given a new $503.00 price target on by analysts at KeyCorp.
• 1/28/2026 – HCA Healthcare had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at UBS Group AG from $525.00 to $598.00. They now have a “buy” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at Oppenheimer Holdings, Inc. from $500.00 to $540.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – HCA Healthcare was given a new $588.00 price target on by analysts at UBS Group AG.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at Cantor Fitzgerald from $525.00 to $588.00. They now have an “overweight” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at KeyCorp from $500.00 to $550.00. They now have an “overweight” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at Barclays PLC from $494.00 to $551.00. They now have an “overweight” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at The Goldman Sachs Group, Inc. from $520.00 to $558.00. They now have a “buy” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at Leerink Partners from $507.00 to $573.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at Jefferies Financial Group Inc. from $535.00 to $590.00. They now have a “buy” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at Royal Bank Of Canada from $525.00 to $555.00. They now have an “outperform” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $500.00 to $558.00. They now have a “buy” rating on the stock.
• 1/28/2026 – HCA Healthcare had its price target raised by analysts at Truist Financial Corporation from $520.00 to $546.00. They now have a “buy” rating on the stock.
• 1/22/2026 – HCA Healthcare had its “overweight” rating reaffirmed by analysts at KeyCorp. They now have a $500.00 price target on the stock.
• 1/22/2026 – HCA Healthcare had its price target raised by analysts at Jefferies Financial Group Inc. from $525.00 to $535.00. They now have a “buy” rating on the stock.
• 1/15/2026 – HCA Healthcare had its price target raised by analysts at Leerink Partners from $470.00 to $507.00. They now have an “outperform” rating on the stock.
• 1/7/2026 – HCA Healthcare had its price target raised by analysts at Wells Fargo & Company from $431.00 to $452.00. They now have an “equal weight” rating on the stock.
• 1/6/2026 – HCA Healthcare had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $503.00 price target on the stock.
• 1/5/2026 – HCA Healthcare had its price target raised by analysts at Truist Financial Corporation from $495.00 to $520.00. They now have a “buy” rating on the stock.
• 12/29/2025 – HCA Healthcare had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – HCA Healthcare had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/19/2025 – HCA Healthcare had its price target raised by analysts at Royal Bank Of Canada from $482.00 to $525.00. They now have an “outperform” rating on the stock.
• 12/18/2025 – HCA Healthcare had its price target raised by analysts at Mizuho from $505.00 to $520.00. They now have an “outperform” rating on the stock.
• 12/15/2025 – HCA Healthcare had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – HCA Healthcare was downgraded by analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating. They now have a $425.00 price target on the stock.
• 12/11/2025 – HCA Healthcare had its price target raised by analysts at Robert W. Baird from $423.00 to $450.00. They now have a “neutral” rating on the stock.

HCA Healthcare Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 17th will be issued a $0.78 dividend. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.72. This represents a $3.12 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Tuesday, March 17th. HCA Healthcare’s dividend payout ratio is 10.15%.

Insider Activity

In other HCA Healthcare news, EVP Michael S. Cuffe sold 1,500 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $498.09, for a total transaction of $747,135.00. Following the sale, the executive vice president directly owned 30,003 shares of the company’s stock, valued at approximately $14,944,194.27. This trade represents a 4.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is currently owned by insiders.

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.